Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

HAYWARD, Calif., Sept. 22 /PRNewswire/ -- Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 24 weeks of treatment with ITCA 650 at all doses.  A starting ITCA 650 dose of 20 mcg/day for weeks 1 through 12 provided effective glycemic control with the best tolerability profile.  A transition to ITCA 650 at 60 mcg/day for weeks 13 through 24 was well tolerated and provided substantial incremental reductions in both HbA1c and body weight at week 24. An ITCA 650 treatment regimen involving a 20 mcg/day starting dose with a transition to 60 mcg/day after week 12 has been selected for a phase 3 clinical trial, anticipated to begin enrollment in early 2011.

"We are very encouraged by the results observed in this study and the high level of enthusiasm expressed by patients and investigators," said Kurt Graves, executive chairman of the board for Intarcia. "ITCA 650 is a novel therapeutic approach for type 2 diabetes that holds new promise for many patients and physicians who want highly effective glucose reductions and weight loss without the tradeoff associated with having to start potentially lifelong and frequent self-injections." Graves added, "ITCA 650 also holds the promise to ensure patient compliance and long-term control given the breakthrough nature of its continuous delivery with just one or two placements
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  Frequentz Inc., a global leader and champion of ... help the pharmaceutical industry understand the current and future ... (DSCSA). The white paper, "From Lot-based to Serialization-based Traceability", ... Standard(s) and Implementation Plan rollout, as well as ... that need to occur between now and the 2017 ...
(Date:3/31/2015)... 2015 Medela has announced the addition ... ® Motion™-Endure personal pumps to its Negative Pressure ... These new devices, along with the Invia ® ... provide innovative, high-quality NPWT solutions, designed to provide ... "We are happy to be able ...
(Date:3/31/2015)... PGI has announced an expansion of its ... at its San Luis Potosi, ... expansion is centered on solving the challenge of complicated ... personal care product manufacturers. The planned ... and packaging, will allow customers to take advantage of ...
Breaking Medicine Technology:Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3Medela Launches Product Line to Support Individualized Care For Negative Pressure Wound Therapy Patients 2PGI Expands Manufacturing Capabilities At Mexico Plant 2
... Sept. 29, 2011 The U.S. Food and Drug ... the International Internet Week of Action (IIWA), a cooperative ... and illegal medical products. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... between Sept. 20 and Sept. 27 is called OPERATION ...
... Sept. 29, 2011 CIVCO ... installed at the Instituto Radioterapia del Este in Puerto ... the Protura system elevates the level of radiation therapy ... need for many patients to travel for treatment. ...
Cached Medicine Technology:FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet 2FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet 3FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet 4CIVCO's Protura™ Installed at Puerto Rico's Instituto Radioterapia del Este 2CIVCO's Protura™ Installed at Puerto Rico's Instituto Radioterapia del Este 3
(Date:3/31/2015)... CT (PRWEB) March 31, 2015 Calling all ... against Lyme and other tick-borne diseases! The first annual “Lyme ... Cove Island Park in Stamford, CT. The event, hosted by ... (TBDA), will raise funds to support research and education ... event, open to all ages and abilities, will feature 5K ...
(Date:3/31/2015)... March 31, 2015 Medical DNA Labs, ... met all criteria for Laboratory Accreditation by COLA, a ... to laboratories that apply rigid standards of quality in ... proficiency testing, and pass a rigorous on-site laboratory survey. ... as a result of a long-term commitment to provide ...
(Date:3/31/2015)... March 31, 2015 Students, teachers, and ... for education in a drastically different way as current ... learning and training content is being delivered and received. ... by technology in an unprecedented way with education becoming ... Cumavoo, co-founder and CEO, My Mobile University , ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Clinovo, ... BayBio’s Membership Program , the premiere voice ... region’s 1300+ life science companies. , BayBio ... the world’s most innovative and productive life science ... solve some of humanity’s most pressing challenges. ...
(Date:3/31/2015)... Scotch Plains, NJ (PRWEB) March 31, 2015 ... the Institute for Advanced Reconstruction. He was recently quoted ... condition is caused by lymphatic issues, causing fluid retention and ... performing the procedure to relieve and / or improve lymphedema ... is to improve or alleviate the symptoms of lymphedema. ...
Breaking Medicine News(10 mins):Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Local Medical DNA Labs, LLC. Recognized for Quality Laboratory Services 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 3Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 4
... form multiple sclerosis had showed marked improvement for ... results of the investigation were reported in the ... ,Although two-thirds of depressed patients prefer psychotherapy to ... a first appointment and nearly half will drop ...
... reduces the spread of gastrointestinal infections in the home. ... the families, which used the hand sanitizer in gel ... of illness related to the gastrointestinal tract. ... study. Half the families were randomly assigned to receive ...
... very old days and it continues to enjoy the privilege ... able to substitute mankind with another alternative. // Very little ... exercise in young competitors. The benefits versus the hazards of ... research has reported that adolescents and young adults involved in ...
... of fibres further by stating that cereal fibre and ... the arteries in postmenopausal women.// ,Previous studies ... risk of heart disease and death. Investigating the effect ... and refined grain products on the progression of existing ...
... Ramadoss Monday said that the government would include ... as it has been emerging as a "problem ... of an Indian Council of Medical Research (ICMR)-World ... diagnosis of leptospirosis at the regional ICMR centre ...
... National University of Singapore studied the effect of plutonium ... cancer// in Plutonium plant workers. The study ... and identification of chromosome aberrations. The study is also ... and disease condition which would be helpful in establishing ...
Cached Medicine News:Health News:MS Patients Improve With Telephone Therapy 2Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Competitive Sports: Is the heart Sportive Enough? 2
... Delta Specialty / Drug Clinical System ... can consolidate Drugs of Abuse, TDM's ... thyroid, HbA1c and lipids in one ... a level of automation and flexibility ...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: